ATE457362T1 - Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs - Google Patents
Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebsInfo
- Publication number
- ATE457362T1 ATE457362T1 AT05843726T AT05843726T ATE457362T1 AT E457362 T1 ATE457362 T1 AT E457362T1 AT 05843726 T AT05843726 T AT 05843726T AT 05843726 T AT05843726 T AT 05843726T AT E457362 T1 ATE457362 T1 AT E457362T1
- Authority
- AT
- Austria
- Prior art keywords
- prostate cancer
- urine
- value
- ratio
- psa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002491067A CA2491067A1 (en) | 2004-12-24 | 2004-12-24 | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
US71955705P | 2005-09-23 | 2005-09-23 | |
PCT/EP2005/014021 WO2006066965A2 (en) | 2004-12-24 | 2005-12-23 | Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE457362T1 true ATE457362T1 (de) | 2010-02-15 |
Family
ID=36636708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05843726T ATE457362T1 (de) | 2004-12-24 | 2005-12-23 | Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs |
Country Status (13)
Country | Link |
---|---|
US (8) | US7960109B2 (de) |
EP (3) | EP2325334A1 (de) |
JP (1) | JP4944041B2 (de) |
AT (1) | ATE457362T1 (de) |
AU (1) | AU2005318369B2 (de) |
CA (2) | CA2491067A1 (de) |
DE (1) | DE602005019294D1 (de) |
DK (1) | DK1761651T3 (de) |
ES (2) | ES2546193T3 (de) |
HK (1) | HK1148315A1 (de) |
IL (1) | IL183476A0 (de) |
WO (1) | WO2006066965A2 (de) |
ZA (1) | ZA200703746B (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
JP3981416B2 (ja) * | 1997-04-10 | 2007-09-26 | ユニバーシティ メディカル センター ナイメーヘン | Pca3タンパク質、pca3遺伝子、及びこれらの用途 |
ATE321857T1 (de) | 1999-09-29 | 2006-04-15 | Diagnocure Inc | Pca3 mrna in gutartigen und bösartigen prostatageweben |
JP4824540B2 (ja) | 2003-02-07 | 2011-11-30 | ダイアノキュアー インク. | サンプル中の前立腺癌を検出する方法 |
US11105808B2 (en) | 2004-11-12 | 2021-08-31 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
JP4943074B2 (ja) * | 2006-07-03 | 2012-05-30 | シスメックス株式会社 | がん転移の判定方法及び装置 |
JP6126773B2 (ja) | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体 |
WO2009085196A1 (en) * | 2007-12-21 | 2009-07-09 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
GB2465088C (en) * | 2008-10-30 | 2016-01-27 | Caris Mpi Inc | miRNA expression in the characterisation and classification of cancer |
JP2012507300A (ja) * | 2008-10-30 | 2012-03-29 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Rnaパターンを評価する方法 |
CN107254538A (zh) * | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
ES2712732T3 (es) | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
JP2010233542A (ja) * | 2009-03-31 | 2010-10-21 | Kanazawa Univ | Rage遺伝子の2種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ |
EP2320234A1 (de) | 2009-11-06 | 2011-05-11 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Markerkombination zur Diagnose von Prostatakrebs |
EP2320235A1 (de) | 2009-11-06 | 2011-05-11 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Markerkombination zur Diagnose von Prostatakrebs |
EP2506876B1 (de) | 2009-12-02 | 2016-10-12 | Imaginab, Inc. | J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
MX346671B (es) * | 2010-04-16 | 2017-03-29 | Hunter Douglas Inc * | Un proceso y sistema para fabricar una persiana enrollable. |
WO2012031207A2 (en) | 2010-09-03 | 2012-03-08 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
DK2630259T3 (en) * | 2010-10-20 | 2015-07-06 | Univ Bordeaux | SIGNATURES OF CLINICAL OUTCOME In gastrointestinal stromal tumors AND METHOD FOR THE TREATMENT OF gastrointestinal stromal tumors |
US9534256B2 (en) | 2011-01-06 | 2017-01-03 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer |
EP2748335B1 (de) * | 2011-08-22 | 2018-10-03 | Exosome Diagnostics, Inc. | Urinbiomarker |
EP2574929A1 (de) | 2011-09-28 | 2013-04-03 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker bei der Diagnose von Prostatakrebs |
EP3495509B1 (de) * | 2013-08-06 | 2021-12-15 | Exosome Diagnostics, Inc. | Urinbiomarkerkohorten, genexpressionssignaturen und verfahren zur verwendung davon |
US10364469B2 (en) | 2014-01-16 | 2019-07-30 | Illumina, Inc | Gene expression panel for prognosis of prostate cancer recurrence |
US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
EP3215634B1 (de) | 2014-11-06 | 2021-08-04 | The Regents of the University of Colorado | Identifizierung neuartiger krankheitszustände mittels viskoelastischer analyse in gegenwart eines thrombolytischen mittels |
US11187710B2 (en) | 2015-06-08 | 2021-11-30 | The Regents Of The University Of Colorado, A Body Corporate | Time independent viscoelastic analysis parameter for prediction of patient outcome |
EP4137158A1 (de) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Gegen moleküle gerichtete antigenbindende konstrukte |
US11871895B2 (en) | 2015-11-24 | 2024-01-16 | The Johns Hopkins University | Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo |
WO2017205074A1 (en) | 2016-05-11 | 2017-11-30 | Chapman Michael P | Viscoelastic analysis in patients with disease associated with the cardiovascular system |
US11913072B2 (en) * | 2016-05-13 | 2024-02-27 | Roche Molecular Systems, Inc. | Detection of MET exon 14 deletions and associated therapies |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
WO2019093530A1 (ja) * | 2017-11-13 | 2019-05-16 | 株式会社リコー | 検出判定用デバイス |
WO2019169336A1 (en) * | 2018-03-02 | 2019-09-06 | The Johns Hopkins University | Methods for prostate cancer detection |
CN110423797A (zh) * | 2019-07-11 | 2019-11-08 | 杨海涛 | 一种前列腺癌pca3基因双重实时pcr的引物、方法及试剂盒 |
CN114743593B (zh) * | 2022-06-13 | 2023-02-24 | 北京橡鑫生物科技有限公司 | 一种基于尿液进行前列腺癌早期筛查模型的构建方法、筛查模型及试剂盒 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2422956A1 (fr) | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4690890A (en) | 1984-04-04 | 1987-09-01 | Cetus Corporation | Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay |
US4786600A (en) | 1984-05-25 | 1988-11-22 | The Trustees Of Columbia University In The City Of New York | Autocatalytic replication of recombinant RNA |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
EP0247091B1 (de) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4851331A (en) * | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
FR2602592B1 (fr) | 1986-08-06 | 1989-06-30 | Alain Baret | Utilisation du systeme enzymatique xanthine-oxydase en immuno-analyse, procedes de dosage correspondants et coffrets de reactifs necessaires pour la mise en oeuvre de ces procedes. |
US5541308A (en) | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5149625A (en) | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
US5639604A (en) | 1987-09-21 | 1997-06-17 | Gen-Probe Incorporated | Homogeneous protection assay |
US5283174A (en) | 1987-09-21 | 1994-02-01 | Gen-Probe, Incorporated | Homogenous protection assay |
US5585481A (en) * | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
US5002867A (en) * | 1988-04-25 | 1991-03-26 | Macevicz Stephen C | Nucleic acid sequence determination by multiple mixed oligonucleotide probes |
NL8801147A (nl) * | 1988-05-02 | 1989-12-01 | Tno | Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit. |
DK167254B1 (da) | 1988-07-21 | 1993-09-27 | Hartmann As Brdr | Fremgangsmaade til fremstilling af formede genstande af et fluidiseret cellulosefibermateriale |
US5183949A (en) * | 1988-09-22 | 1993-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids |
US5118801A (en) * | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
US5219989A (en) * | 1988-12-13 | 1993-06-15 | Mcgill University | Bifunctional protein for the isolation of capped mRNA |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5175383A (en) * | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
US5112736A (en) * | 1989-06-14 | 1992-05-12 | University Of Utah | Dna sequencing using fluorescence background electroblotting membrane |
US5656207A (en) * | 1989-06-24 | 1997-08-12 | Gen Probe Incorporated | Detecting or quantifying multiple analytes using labelling techniques |
US5174986A (en) * | 1989-07-05 | 1992-12-29 | Genpharm International, Inc. | Method for determining oncogenic potential of a chemical compound |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
IE911869A1 (en) | 1990-06-01 | 1991-12-04 | Regeneron Pharma | A family of map2 protein kinases |
AU662906B2 (en) | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
CA2082411A1 (en) * | 1991-06-28 | 1992-12-29 | Robert D. Rosenberg | Localized oligonucleotide therapy |
WO1993003743A1 (en) | 1991-08-16 | 1993-03-04 | The General Hospital Corporation | Method of gene delivery to post-mitotic cells |
AU3129993A (en) | 1991-11-08 | 1993-06-07 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
JPH07502650A (ja) * | 1991-12-16 | 1995-03-23 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | ストレプトミセスにおけるP450soyおよびフェレドキシン−soyの構成性発現、および組み換え体生物による化学物質の生物変換 |
ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
AU681082B2 (en) * | 1992-05-06 | 1997-08-21 | Gen-Probe Incorporated | Nucleic acid sequence amplification method, composition and kit |
US5674682A (en) * | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
WO1994009820A1 (en) | 1992-11-05 | 1994-05-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5773705A (en) * | 1992-12-31 | 1998-06-30 | Wisconsin Alumni Research Foundation | Ubiquitin fusion protein system for protein production in plants |
JPH08505397A (ja) | 1993-01-07 | 1996-06-11 | トーマス ジェファーソン ユニバーシティ | 平滑筋細胞の増殖を調節するためのc‐mycのアンチセンス阻害 |
US5422252A (en) * | 1993-06-04 | 1995-06-06 | Becton, Dickinson And Company | Simultaneous amplification of multiple targets |
US5861242A (en) * | 1993-06-25 | 1999-01-19 | Affymetrix, Inc. | Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US6323184B1 (en) | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
US5925517A (en) * | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
AU687535B2 (en) | 1994-03-16 | 1998-02-26 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
US5976794A (en) | 1994-04-15 | 1999-11-02 | The Trustees Of Columbia University In The City Of New York | Method for molecular staging of prostate cancer |
US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
WO1996011266A2 (en) | 1994-10-05 | 1996-04-18 | Amgen Inc. | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
DE69535240T2 (de) * | 1994-10-28 | 2007-06-06 | Gen-Probe Inc., San Diego | Zusammensetzungen und Verfahren für die gleichzeitige Detektion und Quantifizierung von einer Mehrheit spezifischer Nuklein Säure Sequenzen |
US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
DE19513152A1 (de) * | 1995-04-07 | 1996-10-10 | Bundesrep Deutschland | Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren |
US5731148A (en) | 1995-06-07 | 1998-03-24 | Gen-Probe Incorporated | Adduct protection assay |
AU726821B2 (en) | 1996-07-16 | 2000-11-23 | Gen-Probe Incorporated | Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific Tm |
US6479263B1 (en) * | 1996-11-14 | 2002-11-12 | Baylor College Of Medicine | Method for detection of micrometastatic prostate cancer |
US6800746B2 (en) * | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6261562B1 (en) * | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
HUP0002095A3 (en) * | 1997-02-25 | 2002-02-28 | Corixa Corp Seattle | Compounds for immunotherapy of prostate cancer and methods for their use |
US6395278B1 (en) * | 1997-02-25 | 2002-05-28 | Corixa Corporation | Prostate specific fusion protein compositions |
US6465611B1 (en) * | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
JP3981416B2 (ja) * | 1997-04-10 | 2007-09-26 | ユニバーシティ メディカル センター ナイメーヘン | Pca3タンパク質、pca3遺伝子、及びこれらの用途 |
JP4222635B2 (ja) * | 1997-05-02 | 2009-02-12 | ジェン−プローブ・インコーポレーテッド | 2段階ハイブリダイゼーションおよびポリヌクレオチドの捕捉 |
US6534273B2 (en) | 1997-05-02 | 2003-03-18 | Gen-Probe Incorporated | Two-step hybridization and capture of a polynucleotide |
US6200975B1 (en) * | 1997-05-08 | 2001-03-13 | Merck Sharp & Dohme Limited | Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as GABA alpha 5 ligands |
US6251638B1 (en) * | 1997-05-30 | 2001-06-26 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
US20020035244A1 (en) * | 1997-09-09 | 2002-03-21 | Maurice Cohen | Reagents and methods useful for detecting diseases of the prostate |
US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
US6200765B1 (en) * | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
IL140845A0 (en) | 1998-07-14 | 2002-02-10 | Corixa Corp | Compositions for therapy and diagnosis of prostate cancer |
US6037130A (en) * | 1998-07-28 | 2000-03-14 | The Public Health Institute Of The City Of New York, Inc. | Wavelength-shifting probes and primers and their use in assays and kits |
US6551778B1 (en) | 1999-01-28 | 2003-04-22 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
FI990382A0 (fi) | 1999-02-23 | 1999-02-23 | Arctic Partners Oy Ab | Uusi diagnostinen menetelmä |
US6528260B1 (en) * | 1999-03-25 | 2003-03-04 | Genset, S.A. | Biallelic markers related to genes involved in drug metabolism |
EP1185639B1 (de) | 1999-03-26 | 2010-05-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs |
ATE321857T1 (de) * | 1999-09-29 | 2006-04-15 | Diagnocure Inc | Pca3 mrna in gutartigen und bösartigen prostatageweben |
AU7994200A (en) | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
AU7859900A (en) | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
EP1230364A2 (de) | 1999-11-12 | 2002-08-14 | Corixa Corporation | Zusammensetzungen und verfahren zur behandlung und diagnose von prostatakrebs |
ES2303736T3 (es) | 1999-12-17 | 2008-08-16 | Bio Merieux | Procedimiento para marcar un acido nucleico. |
MXPA02006934A (es) | 2000-01-14 | 2003-01-28 | Corixa Corp | Composiciones y metodos para la terapia y diagnostico de cancer de prostata. |
US20020168638A1 (en) * | 2000-01-24 | 2002-11-14 | Robert Schlegel | Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
WO2001060860A2 (en) | 2000-02-17 | 2001-08-23 | Millennium Predictive Medicine, Inc. | Genes differentially expressed in human prostate cancer and their use |
JP2004504808A (ja) | 2000-03-27 | 2004-02-19 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
FR2810114B1 (fr) | 2000-06-13 | 2002-08-23 | Bio Merieux | Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate |
AU2001292842A1 (en) | 2000-09-19 | 2002-04-02 | Diadexus, Inc. | Compositions and methods relating to prostate specific genes and proteins |
EP1474528A4 (de) | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | Methoden zur diagnose von prostatakrebs, zusammensetzungen und methoden zur untersuchung auf prostatakrebs-modulatoren |
US6897024B2 (en) * | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
JP4824540B2 (ja) * | 2003-02-07 | 2011-11-30 | ダイアノキュアー インク. | サンプル中の前立腺癌を検出する方法 |
CA2432365A1 (en) | 2003-06-30 | 2004-12-30 | Jack A. Schalken | Specific method of prostate cancer detection based on pca3, and kits therefore |
CA2491067A1 (en) * | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
-
2004
- 2004-12-24 CA CA002491067A patent/CA2491067A1/en not_active Abandoned
-
2005
- 2005-12-23 US US11/794,048 patent/US7960109B2/en active Active
- 2005-12-23 ES ES10152258.9T patent/ES2546193T3/es active Active
- 2005-12-23 DK DK05843726.0T patent/DK1761651T3/da active
- 2005-12-23 EP EP10181472A patent/EP2325334A1/de not_active Withdrawn
- 2005-12-23 AU AU2005318369A patent/AU2005318369B2/en active Active
- 2005-12-23 JP JP2007547391A patent/JP4944041B2/ja active Active
- 2005-12-23 AT AT05843726T patent/ATE457362T1/de active
- 2005-12-23 DE DE602005019294T patent/DE602005019294D1/de active Active
- 2005-12-23 ES ES05843726T patent/ES2340513T3/es active Active
- 2005-12-23 WO PCT/EP2005/014021 patent/WO2006066965A2/en active Application Filing
- 2005-12-23 EP EP05843726A patent/EP1761651B1/de active Active
- 2005-12-23 EP EP10152258.9A patent/EP2226394B1/de active Active
- 2005-12-23 CA CA2594125A patent/CA2594125C/en active Active
-
2007
- 2007-05-09 ZA ZA200703746A patent/ZA200703746B/xx unknown
- 2007-05-28 IL IL183476A patent/IL183476A0/en unknown
-
2011
- 2011-03-07 HK HK11102244.7A patent/HK1148315A1/xx unknown
- 2011-05-05 US US13/101,440 patent/US8257924B2/en active Active
-
2012
- 2012-08-09 US US13/571,124 patent/US20120309007A1/en not_active Abandoned
-
2013
- 2013-06-10 US US13/914,303 patent/US9096907B2/en active Active
-
2015
- 2015-06-22 US US14/745,955 patent/US20150307948A1/en not_active Abandoned
-
2016
- 2016-04-13 US US15/097,758 patent/US9951390B2/en active Active
-
2018
- 2018-03-16 US US15/924,040 patent/US10752957B2/en active Active
-
2020
- 2020-08-24 US US17/001,352 patent/US20200392588A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE457362T1 (de) | Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs | |
Fredsøe et al. | Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine | |
Sharma et al. | Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools | |
Harbeck et al. | Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow | |
Turner et al. | Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score | |
Wang et al. | Tumor–ratio–metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients | |
Heinzelmann et al. | MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases | |
WO2006089212A3 (en) | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin | |
ATE373239T1 (de) | Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs | |
DE602006016085D1 (de) | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor | |
EP2762574A1 (de) | Nichtinvasives Diagnoseverfahren zur Diagnose von Blasenkrebs | |
Zehentner et al. | Detection of α-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients | |
WO2008127718A3 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
ATE548656T1 (de) | Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür | |
WO2006113747A3 (en) | Diagnostic markers of breast cancer treatment and progression and methods of use thereof | |
WO2007093657A2 (es) | Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método | |
DE602006020544D1 (de) | Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs | |
JP2013505429A5 (de) | ||
Di Carlo et al. | Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors | |
WO2011154698A3 (en) | Method,array and use thereof | |
Shi et al. | Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles | |
Miyake et al. | Significance of micrometastases in pelvic lymph nodes detected by real‐time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy | |
Bhargava et al. | Luminal B breast tumors are not HER2 positive | |
Wen et al. | Snail as a potential marker for predicting the recurrence of prostate cancer in patients at stage T2 after radical prostatectomy | |
Al-Maghrebi et al. | The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1761651 Country of ref document: EP |